Limitations of model-based dose selection for indacaterol in patients with chronic obstructive pulmonary disease

International Journal of Clinical Pharmacology and Therapeutics

Volumn 50, Issue 9, 2012, Pages 622-630

  Wang, Yaning ^a   Lee, Joo Yeon ^a   Michele, Theresa ^a   Chowdhury, Badrul A ^a   Gobburu, Jogarao V ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Assumption evaluation; Dose selection; Emax model; Indacaterol

Indexed keywords

INDACATEROL; PLACEBO;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MODEL BASED DOSE SELECTION; PROCESS MODEL; SENSITIVITY ANALYSIS;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHODILATOR AGENTS; DECISION SUPPORT TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG APPROVAL; DRUG DISCOVERY; DRUG DOSAGE CALCULATIONS; FORCED EXPIRATORY VOLUME; HUMANS; INDANS; LUNG; MODELS, THEORETICAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; UNITED STATES;

EID: 84866511593     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201758     Document Type: Article

References (7)

1. Chowdhury BA, Seymour SM, Michele TM, Durmowicz AG, Liu D, Rosebraugh CJ. The risks and benefits of indacaterol - the FDA's review. N Engl J Med. 2011; 365: 2247-2249. doi:10.1056/NEJMp1109621 PubMed
2. Renard D, Looby M, Kramer B, Lawrence D, Morris D, Stanski DR. Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches. Respir Res. 2011; 12: 54. doi:10.1186/1465-9921-12-54http://respiratory-research.com/ content/12/1/54. Accessed February 8, 2012. PubMed
3. Indacaterol product label, http://www.accessdata. fda.gov/drugsatfda- docs/label/2011/022383s000lbl.pdf. Accessed February 8, 2012.
4. Borenstein M, Hedges LV, Higgins JPT et al. Introduction to meta-analysis. West Sussex, UK: John Wiley & Sons, Ltd; 2009.
5. Sturtz S, Ligges U, Gelman A. R2WinBUGS: A package for running WinBUGS from R. J Stat Softw. 2005; 12: 1-16.
6. FDA Advisory Committee Meeting minutes for indacaterol, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM250243.pdf. Accessed February 8, 2012.
7. FDA critical path opportunities list, http://www.fda.gov/downloads/ ScienceResearch/SpecialTopics/CriticalPathInitiative/ CriticalPathOpportunitiesReports/UCM077258.pdf. Accessed February 8, 2012.